The main products of the group: Tiantianxiangshang tablet is a children's health food to promote growth and improve memory; Li Deyi tablet is an environment-friendly lead-discharging health food, which has been patented by China and the United States, reaching the international leading level and winning the third prize of Sichuan Science and Technology Progress; Benmi capsule is a new calcium supplement product with soybean isoflavone, which can effectively increase the bone density of middle-aged and elderly people. Runnuo Tablet is a nutritional supplement specially designed for women in China, especially for pregnant women in China. Koufu capsule is a health food specially developed for people with hypoglycemia or diabetic patients whose blood sugar is controlled by diet to reduce postprandial blood sugar. It is named Koufu Capsule because it can increase patients' oral happiness. Sanguotang buccal tablet is a Tibetan medicine product with targeted immunity and both symptoms and root causes, which is suitable for patients with chronic pharyngitis in the early and late stages of plague fever. Wuling Congrong mixture is a traditional Chinese medicine product specially developed for treating various deficiency diseases of middle-aged and elderly people according to the theory of invigorating spleen and kidney in traditional Chinese medicine.
In addition, the company also has 57 generic drugs, covering common diseases, frequently-occurring diseases and other diseases.
The Group has set a strategic goal, that is, to establish a high-standard traditional Chinese medicine with three general practitioners in the near future, and to upgrade China's medical care products. First of all, if we want to use modern science and technology to develop effective, safe and effective Chinese medicine health care products, we must keep up with the international level in product research and development. The Group invested more than 6,543,800 yuan to build its subsidiary Sichuan Institute of Natural Medicine into a GLP laboratory meeting the national quality management standards for non-clinical drug research.
The Group firmly grasped the advantages of traditional Chinese medicine and health care traditional Chinese medicine, and formulated the "350" development strategy, namely, three years' rapid development, five years' rapid development and ten years' rapid development. By 2020, the enterprise will complete five general practitioners in the pharmaceutical industry. It has reached the higher level of Chinese medicine industry and the first-class level of health care industry in China. 3-5 Chinese medicine products have been cast to become national famous brands, 2-3 health care products have become national singles champions, and a Chinese medicine health care product has been cast to become a brand with a certain international reputation.